Comparison of two lab-scale protocols for enhanced mRNA-based CAR-T cell generation and functionality

Process development for transferring lab-scale research workflows to automated manufacturing procedures is critical for chimeric antigen receptor (CAR)-T cell therapies. Therefore, the key factor for cell viability, expansion, modification, and functionality is the optimal combination of medium and...

Descripción completa

Detalles Bibliográficos
Autores principales: von Auw, Nadine, Serfling, Robert, Kitte, Reni, Hilger, Nadja, Zhang, Chengkang, Gebhardt, Clara, Duenkel, Anna, Franz, Paul, Koehl, Ulrike, Fricke, Stephan, Tretbar, U. Sandy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598065/
https://www.ncbi.nlm.nih.gov/pubmed/37875523
http://dx.doi.org/10.1038/s41598-023-45197-x
Descripción
Sumario:Process development for transferring lab-scale research workflows to automated manufacturing procedures is critical for chimeric antigen receptor (CAR)-T cell therapies. Therefore, the key factor for cell viability, expansion, modification, and functionality is the optimal combination of medium and T cell activator as well as their regulatory compliance for later manufacturing under Good Manufacturing Practice (GMP). In this study, we compared two protocols for CAR-mRNA-modified T cell generation using our current lab-scale process, analyzed all mentioned parameters, and evaluated the protocols’ potential for upscaling and process development of mRNA-based CAR-T cell therapies.

Ejemplares similares